Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice
Volume: 16, Issue: 10, Pages: 1019 - 1028
Published: Sep 29, 2020
Abstract
After patents' expiration of biological originators, several biosimilars of infliximab and adalimumab have been authorized. The approval is based on data extrapolated from other indications for which the originator has been previously tested. Despite rigorous approval processes by regulatory entities, physicians' and patients' knowledge about biosimilars is limited and some concerns about their use persist.This article summarizes the evidence on...
Paper Details
Title
Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice
Published Date
Sep 29, 2020
Volume
16
Issue
10
Pages
1019 - 1028
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History